<?xml version="1.0" encoding="UTF-8"?>

<rss version="2.0"
 xmlns:blogChannel="http://backend.userland.com/blogChannelModule"
>

<channel>
<title>Cancer Network</title>
<link></link>
<description>Cancer Screening, Diagnosis, Treatment, Prevention - Practical Reviews &#x26; Free CME - Cancer Network
</description>
<language>en</language>
<copyright>Copyright 2009, CMPMedica US</copyright>
<pubDate>Wed, 19 Jun 2013 13:30:02 GMT</pubDate>
<lastBuildDate>Wed, 19 Jun 2013 13:30:02 GMT</lastBuildDate>
<docs>http://blogs.law.harvard.edu/tech/rss</docs>

<item>
<title>ASCO: Dabrafenib Shows Activity in BRAF-Mutated NSCLC Patients</title>
<link>http://www.cancernetwork.com/lung-cancer/content/article/10165/2147206?CID=rss</link>
<description>&#x3C;img src=&#x22;http://www.cancernetwork.com/image/image_gallery?img_id=2147333&#x26;t=1371594208813&#x22; align=&#x22;left&#x22; width=&#x22;48&#x22; height=&#x22;48&#x22; style=&#x22;margin-right:5px; margin-top:2px; border:1px solid black;&#x22;/&#x3E;Interim results of a small phase II study found a relatively good response rate with dabrafenib in BRAF V600E mutation-positive stage IV non-small-cell lung cancer (NSCLC) patients. The results were presented at ASCO.&#x3C;br style=&#x22;clear:both;&#x22;/&#x3E;</description>
<pubDate>Tue, 18 Jun 2013 12:00:00 GMT</pubDate>
</item>
<item>
<title>Preventing Burnout in Oncology</title>
<link>http://www.cancernetwork.com/practice-management/content/article/10165/2147201?CID=rss</link>
<description>&#x3C;img src=&#x22;http://www.cancernetwork.com/image/image_gallery?img_id=2147421&#x26;t=1371592319906&#x22; align=&#x22;left&#x22; width=&#x22;48&#x22; height=&#x22;48&#x22; style=&#x22;margin-right:5px; margin-top:2px; border:1px solid black;&#x22;/&#x3E;Developing an effective personal and professional self-care plan can help oncologists deal with the pressures of caring for terminally ill patients and potentially prevent burnout, a recent study suggests.&#x3C;br style=&#x22;clear:both;&#x22;/&#x3E;</description>
<pubDate>Tue, 18 Jun 2013 12:00:00 GMT</pubDate>
</item>
<item>
<title>ASCO: Yoga Reduces Insomnia in Breast Cancer Patients Treated With Hormone Therapy</title>
<link>http://www.cancernetwork.com/nurses/content/article/10165/2147288?CID=rss</link>
<description>&#x3C;img src=&#x22;http://www.cancernetwork.com/image/image_gallery?img_id=2147295&#x26;t=1371587905736&#x22; align=&#x22;left&#x22; width=&#x22;48&#x22; height=&#x22;48&#x22; style=&#x22;margin-right:5px; margin-top:2px; border:1px solid black;&#x22;/&#x3E;The use of a yoga program helped to reduce symptoms of insomnia among women with breast cancer undergoing hormonal therapy, and also resulted in an improved quality of life, according to new data presented at ASCO.&#x3C;br style=&#x22;clear:both;&#x22;/&#x3E;</description>
<pubDate>Tue, 18 Jun 2013 12:00:00 GMT</pubDate>
</item>
<item>
<title>The Role of Physical Activity in Cancer Prevention, Treatment, Recovery, and Survivorship</title>
<link>http://www.cancernetwork.com/survivorship/content/article/10165/2146815?CID=rss</link>
<description>&#x3C;img src=&#x22;http://www.cancernetwork.com/image/image_gallery?img_id=2147407&#x26;t=1371589999497&#x22; align=&#x22;left&#x22; width=&#x22;48&#x22; height=&#x22;48&#x22; style=&#x22;margin-right:5px; margin-top:2px; border:1px solid black;&#x22;/&#x3E;This article will review these intersections of exercise and oncology, discuss the known mechanisms by which exercise exerts its salutary effects, and touch upon the future directions of exercise research in the oncology setting. Finally, recommendations are provided for clinicians to help patients with and without cancer take advantage of the benefits of physical activity.&#x3C;br style=&#x22;clear:both;&#x22;/&#x3E;</description>
<pubDate>Tue, 18 Jun 2013 12:00:00 GMT</pubDate>
</item>
<item>
<title>Tailored Therapy in Diffuse Gliomas: Using Molecular Classifiers to Optimize Clinical Management</title>
<link>http://www.cancernetwork.com/brain-tumors/content/article/10165/2145827?CID=rss</link>
<description>&#x3C;img src=&#x22;http://www.cancernetwork.com/image/image_gallery?img_id=2147318&#x26;t=1371573843288&#x22; align=&#x22;left&#x22; width=&#x22;48&#x22; height=&#x22;48&#x22; style=&#x22;margin-right:5px; margin-top:2px; border:1px solid black;&#x22;/&#x3E;We review the current data regarding the prognostic and predictive value of IDH mutation and 1p/19q codeletion in gliomas. We also discuss possible management algorithms using these biomarkers to tailor surgical and adjuvant therapy for specific diffuse gliomas.&#x3C;br style=&#x22;clear:both;&#x22;/&#x3E;</description>
<pubDate>Tue, 18 Jun 2013 12:00:00 GMT</pubDate>
</item>
<item>
<title>The Key to Improving Survival in Ovarian Cancer: Better Screening of Women With Vague Symptoms, Leading to Earlier Diagnosis, More Effective Surgery</title>
<link>http://www.cancernetwork.com/ovarian-cancer/content/article/10165/2145822?CID=rss</link>
<description>Although the combination of CA-125 and HE4 appears indicated for use in symptomatic patients or in patients with an adnexal mass, there is no evidence that it would be indicated as a screening test in asymptomatic patients.</description>
<pubDate>Tue, 18 Jun 2013 12:00:00 GMT</pubDate>
</item>
<item>
<title>The Emerging Role of HE4 in the Evaluation of Epithelial Ovarian and Endometrial Carcinomas</title>
<link>http://www.cancernetwork.com/gynecologic-cancer/content/article/10165/2145871?CID=rss</link>
<description>&#x3C;img src=&#x22;http://www.cancernetwork.com/image/image_gallery?img_id=2147308&#x26;t=1371567641552&#x22; align=&#x22;left&#x22; width=&#x22;48&#x22; height=&#x22;48&#x22; style=&#x22;margin-right:5px; margin-top:2px; border:1px solid black;&#x22;/&#x3E;In this review, we discuss the discovery and biologic significance of HE4 and evaluate available evidence regarding the utility of HE4 as a biomarker for ovarian and endometrial cancer.&#x3C;br style=&#x22;clear:both;&#x22;/&#x3E;</description>
<pubDate>Tue, 18 Jun 2013 12:00:00 GMT</pubDate>
</item>
<item>
<title>Bladder Cancer Recurrence High, Better Follow-Up Care Needed</title>
<link>http://www.cancernetwork.com/genitourinary-cancer/content/article/10165/2147048?CID=rss</link>
<description>&#x3C;img src=&#x22;http://www.cancernetwork.com/image/image_gallery?img_id=2147055&#x26;t=1371498131213&#x22; align=&#x22;left&#x22; width=&#x22;48&#x22; height=&#x22;48&#x22; style=&#x22;margin-right:5px; margin-top:2px; border:1px solid black;&#x22;/&#x3E;Recent studies suggest patients with bladder cancer are not receiving optimal care or the follow-up surveillance as recommended by the National Comprehensive Cancer Network (NCCN).&#x3C;br style=&#x22;clear:both;&#x22;/&#x3E;</description>
<pubDate>Mon, 17 Jun 2013 12:00:00 GMT</pubDate>
</item>
<item>
<title>ASCO: Post-Surgery Surveillance Found Safe in Seminoma</title>
<link>http://www.cancernetwork.com/genitourinary-cancer/content/article/10165/2147043?CID=rss</link>
<description>&#x3C;img src=&#x22;http://www.cancernetwork.com/image/image_gallery?img_id=2147037&#x26;t=1371486018372&#x22; align=&#x22;left&#x22; width=&#x22;48&#x22; height=&#x22;48&#x22; style=&#x22;margin-right:5px; margin-top:2px; border:1px solid black;&#x22;/&#x3E;Surveillance of patients with stage I seminoma following orchiectomy can spare a majority of patients from adjuvant chemotherapy with a low risk of relapse, according to results presented at the 2013 ASCO meeting.&#x3C;br style=&#x22;clear:both;&#x22;/&#x3E;</description>
<pubDate>Mon, 17 Jun 2013 12:00:00 GMT</pubDate>
</item>
<item>
<title>Postmenopausal Hormone Receptor&#x2013;Positive Advanced Breast Cancer</title>
<link>http://www.cancernetwork.com/breast-cancer/content/article/10165/2145886?CID=rss</link>
<description>&#x3C;img src=&#x22;http://www.cancernetwork.com/image/image_gallery?img_id=2146990&#x26;t=1371480058977&#x22; align=&#x22;left&#x22; width=&#x22;48&#x22; height=&#x22;48&#x22; style=&#x22;margin-right:5px; margin-top:2px; border:1px solid black;&#x22;/&#x3E;The goals of care for patients with hormone receptor (HR)-positive advanced breast cancer include prolongation of disease-free and overall survival, amelioration of symptoms, and improvement in quality of life.&#x3C;br style=&#x22;clear:both;&#x22;/&#x3E;</description>
<pubDate>Mon, 17 Jun 2013 12:00:00 GMT</pubDate>
</item>
<item>
<title>Fertility Preservation and Breast Cancer: A Complex Problem</title>
<link>http://www.cancernetwork.com/breast-cancer/content/article/10165/2145852?CID=rss</link>
<description>&#x3C;img src=&#x22;http://www.cancernetwork.com/image/image_gallery?img_id=2146999&#x26;t=1371480930840&#x22; align=&#x22;left&#x22; width=&#x22;48&#x22; height=&#x22;48&#x22; style=&#x22;margin-right:5px; margin-top:2px; border:1px solid black;&#x22;/&#x3E;A considerable number of women with breast cancer are diagnosed during their reproductive years. In the short period of time in which newly diagnosed women will need to make decisions about surgical options and adjuvant therapy, younger women with breast cancer also face the potential impairment or complete loss of their fertility. &#x3C;br style=&#x22;clear:both;&#x22;/&#x3E;</description>
<pubDate>Mon, 17 Jun 2013 12:00:00 GMT</pubDate>
</item>
<item>
<title>Metaplastic Mammary Carcinoma With Discrepant Hormone Receptor Results by IHC and RT-PCR</title>
<link>http://www.cancernetwork.com/breast-cancer/content/article/10165/2145847?CID=rss</link>
<description>&#x3C;img src=&#x22;http://www.cancernetwork.com/image/image_gallery?img_id=2146986&#x26;t=1371479787971&#x22; align=&#x22;left&#x22; width=&#x22;48&#x22; height=&#x22;48&#x22; style=&#x22;margin-right:5px; margin-top:2px; border:1px solid black;&#x22;/&#x3E;The Case: A 48-year-old perimenopausal woman noted a lump in her left breast. She had had a mammogram 9 months earlier without abnormality. After ultrasound imaging confirmed a solitary mass measuring about 1.5 cm, a core needle biopsy demonstrated a poorly differentiated mammary carcinoma with chondroid features.&#x3C;br style=&#x22;clear:both;&#x22;/&#x3E;</description>
<pubDate>Mon, 17 Jun 2013 12:00:00 GMT</pubDate>
</item>
<item>
<title>Intermittent Imatinib for Elderly CML Patients Shows Promise</title>
<link>http://www.cancernetwork.com/chronic-myeloid-leukemia/content/article/10165/2146936?CID=rss</link>
<description>&#x3C;img src=&#x22;http://www.cancernetwork.com/image/image_gallery?img_id=2146943&#x26;t=1371248378153&#x22; align=&#x22;left&#x22; width=&#x22;48&#x22; height=&#x22;48&#x22; style=&#x22;margin-right:5px; margin-top:2px; border:1px solid black;&#x22;/&#x3E;A phase II study found that an alternative imatinib treatment schedule for elderly patients with chronic myeloid leukemia (CML) could be an effective way to reduce dosing requirements of the drug. &#x3C;br style=&#x22;clear:both;&#x22;/&#x3E;</description>
<pubDate>Fri, 14 Jun 2013 12:00:00 GMT</pubDate>
</item>
<item>
<title>Vegetable Fats May Reduce Risk of Death in Prostate Cancer Patients</title>
<link>http://www.cancernetwork.com/prostate-cancer/content/article/10165/2146661?CID=rss</link>
<description>&#x3C;img src=&#x22;http://www.cancernetwork.com/image/image_gallery?img_id=2146959&#x26;t=1371249115732&#x22; align=&#x22;left&#x22; width=&#x22;48&#x22; height=&#x22;48&#x22; style=&#x22;margin-right:5px; margin-top:2px; border:1px solid black;&#x22;/&#x3E;A new study shows that men diagnosed with prostate cancer may do better by substituting carbohydrates and saturated fats with plant-based fats such as those found in nuts and olive oil.&#x3C;br style=&#x22;clear:both;&#x22;/&#x3E;</description>
<pubDate>Fri, 14 Jun 2013 12:00:00 GMT</pubDate>
</item>
<item>
<title>Imatinib Discontinuation in Chronic Phase CML Doesn&#x2019;t Always Lead to Relapse</title>
<link>http://www.cancernetwork.com/chronic-myeloid-leukemia/content/article/10165/2146666?CID=rss</link>
<description>&#x3C;img src=&#x22;http://www.cancernetwork.com/image/image_gallery?img_id=2146934&#x26;t=1371245520599&#x22; align=&#x22;left&#x22; width=&#x22;48&#x22; height=&#x22;48&#x22; style=&#x22;margin-right:5px; margin-top:2px; border:1px solid black;&#x22;/&#x3E;Almost half of patients with chronic-phase chronic myeloid leukemia (CML) who discontinued imatinib treatment did not relapse, according to results of a prospective study. Those who did relapse showed continued sensitivity to imatinib when treatment started again.&#x3C;br style=&#x22;clear:both;&#x22;/&#x3E;</description>
<pubDate>Fri, 14 Jun 2013 12:00:00 GMT</pubDate>
</item>
<item>
<title>ASCO: Cetuximab Ups Survival Over Bevacizumab in Colorectal Cancer</title>
<link>http://www.cancernetwork.com/conference-reports/asco2013/content/article/10165/2146672?CID=rss</link>
<description>&#x3C;img src=&#x22;http://www.cancernetwork.com/image/image_gallery?img_id=2146926&#x26;t=1371241054718&#x22; align=&#x22;left&#x22; width=&#x22;48&#x22; height=&#x22;48&#x22; style=&#x22;margin-right:5px; margin-top:2px; border:1px solid black;&#x22;/&#x3E;Results from the German AIO KRK-0306 study, FIRE-3, show that the addition of cetuximab (Erbitux) to chemotherapy rather than bevacizumab (Avastin) increased overall survival by nearly 4 months in patients with KRAS wild-type metastatic colorectal cancer.&#x3C;br style=&#x22;clear:both;&#x22;/&#x3E;</description>
<pubDate>Fri, 14 Jun 2013 12:00:00 GMT</pubDate>
</item>
<item>
<title>Supreme Court Ruling Invalidates Myriad&#x2019;s BRCA Gene Patents</title>
<link>http://www.cancernetwork.com/display/article/10165/2146788?CID=rss</link>
<description>&#x3C;img src=&#x22;http://www.cancernetwork.com/image/image_gallery?img_id=2146799&#x26;t=1371226355293&#x22; align=&#x22;left&#x22; width=&#x22;48&#x22; height=&#x22;48&#x22; style=&#x22;margin-right:5px; margin-top:2px; border:1px solid black;&#x22;/&#x3E;The Supreme Court announced a unanimous 9-0 decision that genes cannot be patented. After a long legal battle, the high court ruled against Myriad&#x2019;s patents on two breast cancer susceptibility genes&#x2014;BRCA1 and BRCA2&#x2014;declaring that genes are products of nature and cannot be treated as inventions.&#x3C;br style=&#x22;clear:both;&#x22;/&#x3E;</description>
<pubDate>Fri, 14 Jun 2013 12:00:00 GMT</pubDate>
</item>
<item>
<title>When Do You Recommend Molecular Profiling of Tumors?</title>
<link>http://www.cancernetwork.com/poll/content/article/10165/2146748?CID=rss</link>
<description>&#x3C;img src=&#x22;http://www.cancernetwork.com/image/image_gallery?img_id=2146795&#x26;t=1371227570360&#x22; align=&#x22;left&#x22; width=&#x22;48&#x22; height=&#x22;48&#x22; style=&#x22;margin-right:5px; margin-top:2px; border:1px solid black;&#x22;/&#x3E;How often do you refer patients for molecular profiling of a malignant tumor? For which of the following tumor types would you be most likely to recommend molecular profiling? Answer these questions and more.&#x3C;br style=&#x22;clear:both;&#x22;/&#x3E;</description>
<pubDate>Fri, 14 Jun 2013 12:00:00 GMT</pubDate>
</item>
<item>
<title>ASCO: Sunitinib Improves PFS in Small-Cell Lung Cancer</title>
<link>http://www.cancernetwork.com/lung-cancer/content/article/10165/2146433?CID=rss</link>
<description>&#x3C;img src=&#x22;http://www.cancernetwork.com/image/image_gallery?img_id=2146419&#x26;t=1370983648220&#x22; align=&#x22;left&#x22; width=&#x22;48&#x22; height=&#x22;48&#x22; style=&#x22;margin-right:5px; margin-top:2px; border:1px solid black;&#x22;/&#x3E;A randomized, phase II trial showed improved progression-free survival in small-cell lung cancer with maintenance sunitinib vs placebo following standard chemotherapy, according to results presented at the ASCO annual meeting in Chicago.&#x3C;br style=&#x22;clear:both;&#x22;/&#x3E;</description>
<pubDate>Wed, 12 Jun 2013 12:00:00 GMT</pubDate>
</item>
</channel>
</rss>